Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.

JAMA network open - 2 Oct 2023

Olivier Timothée, Haslam Alyson, Tuia Jordan, Prasad Vinay

Abstract excerpt

Importance: The development of therapeutics for patients who are positive for specific human leukocyte antigen (HLA) subtypes evokes the question of whether certain racial and ethnic groups are more or less likely to be eligible for novel products. Objective: To determine whether racial and ethnic inequities were present with regard to trial eligibility in trials investigating a therapeutic restricted to patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Cross-Sectional Studies
Share to Ethnicity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-A Antigens

Share to HLA Antigens

Source

Open in PubMed Open full text

Identifiers

PMID: 37883087
DOI: 10.1001/jamanetworkopen.2023.38612
PMCID: PMC10603498

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.PMID 37883087Read ↗

Ensuring equity in the era of HLA-restricted cancer therapeuticsSemantic proximity Read ↗

Racial and Ethnic Diversity in Clinical Studies Reported to ClinicalTrials.gov, 2009-2024Semantic proximity Read ↗

A Systematic Review of Representation in Clinical Trials for Transthyretin Associated Cardiac Amyloidosis: Where Demographics Diverge from DiseaseSemantic proximity Read ↗

The Current Landscape of Clinical TrialsSemantic proximity Read ↗

New Benchmarks on Demographic Disparities in Pivotal Trials Supporting FDA Approved Drugs and BiologicsSemantic proximity Read ↗

Adequate Underrepresented Minority Representation in Cancer Trials: Evidence from an NCI-Designated Center in a Minority CountySemantic proximity Read ↗

Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations.Semantic proximity Read ↗

Analysis of Racial/Ethnic Representation in Select Basic and Applied Cancer Research StudiesSemantic proximity Read ↗

Characteristics and Developmental Trajectory of Clinical Trials Focused on Tumor-Infiltrating Lymphocytes for Cancer TreatmentSemantic proximity Read ↗

Current State and Demographic Trends of Medically Underserved Populations in Rare Disease Research in the United StatesSemantic proximity Read ↗

Sociodemographic Bias in Large Language Model Clinical Trial ScreeningSemantic proximity Read ↗

The UPTAKE study: Implications for the future of COVID-19 vaccination trial recruitment in UK and beyondSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.